Public health clinical medical center of Chengdu
Welcome,         Profile    Billing    Logout  
 1 Trial 
3 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Wu, Guihui
NCT06476210: The Safety and Efficacy of BDL(Bedaquiline Plus Delamanid Plus Linezolid) Regimen in Subjects With Pulmonary Infection of Multi-drug Resistant Tuberculosis (MDR-TB) or Rifampicin-Resistant Tuberculosis (RR-TB)

Recruiting
4
45
RoW
BDL regimen
Beijing Chest Hospital, Public Health Clinical Medical Center of Chengdu, Wuhan Institute for Tuberculosis Control, Changsha Central Hospital, Anhui Chest Hospital, Hunan Chest Hospital, Shandong Public Health Clinical Center
Pulmonary Tuberculosis
06/25
06/26
PROSPECT, NCT05306223: A Study of an Oral Short-course Regimen Including Bedaquiline for the Treatment of Participants With Multidrug-resistant Tuberculosis in China

Recruiting
4
212
RoW
Bedaquiline, SIRTURO, Levofloxacin, Linezolid, Cycloserine, Clofazimine, Pyrazinamide, Protionamide
Beijing Chest Hospital
Tuberculosis, Multidrug-Resistant
08/25
08/25
NCT06305104: Clinical Trial to Explore the Skin Test Dosage of EEC in People Aged 18 to 65 Years Old and the Safety and Preliminary Efficacy in People Aged 3 to 75 Years Old.

Recruiting
2
420
RoW
2.5μg/ml EEC, 5μg/ml EEC, 5 unit（U） EC
Chengdu CoenBiotech Co., Ltd, Beijing Chest Hospital, Capital Medical University, Wuhan Institute for Tuberculosis Control, The Public Health Clinical Center of Chengdu, Xuzhou Infectious Disease Hospital, Jiangsu Province Centers for Disease Control and Prevention, Changde First People's Hospital
Tuberculosis
05/24
06/24
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Wu, Guihui
NCT06476210: The Safety and Efficacy of BDL(Bedaquiline Plus Delamanid Plus Linezolid) Regimen in Subjects With Pulmonary Infection of Multi-drug Resistant Tuberculosis (MDR-TB) or Rifampicin-Resistant Tuberculosis (RR-TB)

Recruiting
4
45
RoW
BDL regimen
Beijing Chest Hospital, Public Health Clinical Medical Center of Chengdu, Wuhan Institute for Tuberculosis Control, Changsha Central Hospital, Anhui Chest Hospital, Hunan Chest Hospital, Shandong Public Health Clinical Center
Pulmonary Tuberculosis
06/25
06/26
PROSPECT, NCT05306223: A Study of an Oral Short-course Regimen Including Bedaquiline for the Treatment of Participants With Multidrug-resistant Tuberculosis in China

Recruiting
4
212
RoW
Bedaquiline, SIRTURO, Levofloxacin, Linezolid, Cycloserine, Clofazimine, Pyrazinamide, Protionamide
Beijing Chest Hospital
Tuberculosis, Multidrug-Resistant
08/25
08/25
NCT06305104: Clinical Trial to Explore the Skin Test Dosage of EEC in People Aged 18 to 65 Years Old and the Safety and Preliminary Efficacy in People Aged 3 to 75 Years Old.

Recruiting
2
420
RoW
2.5μg/ml EEC, 5μg/ml EEC, 5 unit（U） EC
Chengdu CoenBiotech Co., Ltd, Beijing Chest Hospital, Capital Medical University, Wuhan Institute for Tuberculosis Control, The Public Health Clinical Center of Chengdu, Xuzhou Infectious Disease Hospital, Jiangsu Province Centers for Disease Control and Prevention, Changde First People's Hospital
Tuberculosis
05/24
06/24

Download Options